Trial reportFrontiers in nutrition2025
A phase II clinical trial of
Trial report in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.Cancer immunology, immunotherapy : CII · 2026Review
- The role of the gut microbiota in radiation enteritis: from mechanistic insights to therapeutic applications.Communications biology · 2026Review
- Gut microbiota and microbiota-derived metabolites in radiation-induced injury: mechanisms and therapeutic opportunities.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute radiation enteritis (ARE) is a common side effect experienced by patients receiving pelvic radiotherapy (RT). Probiotic supplementation is an emerging strategy for preventing ARE. Methods: This phase II trial recruited patients with gynecologic or rectal cancers who received pelvic RT with curative or adjuvant intent. During RT, one packet of Results: This study enrolled 52 patients, 8 participants withdrew, and 44 patients being included in the final analysis. The safety profile of BL21 during RT was favorable, and we did not observe any serious adverse events associated with BL21. Compared with our historical control data, these patients exhibited lower levels of ≥ grade 2 ARE and required fewer antidiarrheal medications ( Conclusions: The favorable safety profile, exploratory clinical observations of reduced ARE severity vs. historical controls, and feasible administration support further investigation of Clinical Trial Registration: Chinese Clinical Study Registry (registry ID: ChiCTR2300069881).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.